Kwality Pharmaceuticals shares surged 10.40% to hit a 52-week high of ₹2,206.55 per share on the BSE following the announcement of strong Q4FY26 results. According to reports from Business Standard, the stock continued trading higher at 11:04 AM, with shares at ₹2,135 apiece, up 6.83% from the previous close of ₹1,998.55 per share. The counter outperformed the benchmark BSE Sensex, which was trading lower by 213 points at 74,988 levels during the same period. Latest data shows the stock has extended its winning streak to five consecutive sessions, surging to a fresh all-time high of ₹1,920 on 19 May 2026, outperforming its sector and the broader market with notable volatility and strong volume support.
For Q4FY26, Kwality Pharmaceuticals reported its highest-ever quarterly revenue of ₹157.11 crore, registering a Year-on-Year growth of 35.8% from ₹115.67 crore in the corresponding quarter last year. As reported by Business Standard, for the full year FY26, the company reported consolidated revenue of ₹503 crore, compared with ₹370 crore in FY25, reflecting a growth of 36% Y-o-Y. The company's Ebitda margin improved to 24%, expanding by around 200 basis points from 22% in FY25, driven by better product mix and higher contribution from regulated markets.
Profit after tax (PAT) for FY26 stood at ₹67.34 crore, compared with ₹39.80 crore in FY25, representing a growth of nearly 69% Y-o-Y. According to the company's exchange filing reported by Business Standard, PAT margins expanded by around 260 basis points to 13.4% in FY26 from 10.8% in FY25, reflecting improved operational efficiencies and better realisations. The improvement was attributed to tighter cost controls across the value chain and higher contribution from regulated markets. Latest reports show the company delivered an exceptional Q4FY26 consolidated net profit of ₹25.30 crores, marking a remarkable 74.60% surge year-on-year and 58.03% jump quarter-on-quarter, cementing a year of robust operational momentum.
The company announced a dividend of ₹2 per equity share of ₹1 each for FY26, further supporting investor sentiment. As reported by Business Standard, looking ahead, Kwality Pharmaceuticals remains on track to achieve its FY27 guidance of ₹650 crore in revenue and ₹100 crore in PAT. Management indicated there remains potential upside to the guidance, depending on the pace of approvals, registrations, and commercialisation across key international markets. The company continues to target a doubling of revenues over the next three years, with an aspirational milestone of achieving ₹1,000 crore in topline revenue by FY29.
